Last reviewed · How we verify
NCT05498974
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
trial testing Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center in Type1diabetes in 20,000 participants. Currently enrolling.
31 December 2035
Quick facts
| Lead sponsor | Second Xiangya Hospital of Central South University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20,000 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2035 |
| Estimated completion | 31 December 2035 |
| Sites | 11 locations across China |
Drugs / interventions tested
- Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Conditions studied
- Type1diabetes — all drugs for Type1diabetes →
- Diabetes — all drugs for Diabetes →
Sponsor
Second Xiangya Hospital of Central South University
Who can join
Eligibility, any sex, with Type1diabetes or Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset \<= 20 years. CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Health Inequities in Older Adults With Type 1 Diabetes: A Nationwide Registry Analysis of Sociodemographic and Clinical Profiles for Glycaemic Control and Complications.
Deng C, Fan W, Xie Y, Tang X, et al · · 2026 · PMID 42152598 · DOI 10.1111/dom.70833
Verify or expand the search:
- PubMed search for NCT05498974
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type1diabetes
Currently open trials in the same condition.
- NCT07139808 — Safety and Effectiveness of A Novel Continuous Glucose and Ketone Monitoring System · NA · recruiting
- NCT07092761 — Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System · NA · recruiting
- NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
- NCT06753994 — Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors · Phase 1 · recruiting
- NCT05668507 — REACHOUT Mental Health Support Mobile App · NA · active not recruiting
Other Second Xiangya Hospital of Central South University trials
Trials by the same sponsor.
- NCT07278947 — ACT-based Parenting Program for Caregivers of Children With Hearing Loss Post-cochlear: A Pilot Randomised Controlled Tr · NA · not yet recruiting
- NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07343154 — Multimodal Brain Function in Migraine Patients With Patent Foramen Ovale · not yet recruiting
- NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05498974 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Xiangya Hospital of Central South University
- Last refreshed: 12 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498974.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing